Journal: Molecular Cancer

Article Title: Targeting of erbB3 receptor to overcome resistance in cancer treatment

doi: 10.1186/1476-4598-13-105

Figure Lengend Snippet: ErbB3 interacts with erbB2 to activate signaling pathways leading to multi-drug resistance in breast cancer. Hetero-dimerization of erbB2 and erbB3 is able to induce activation of multiple downstream signaling pathways. In both luminal B and erbB2+ subtypes of human breast cancer, erbB2/erbB3 association may recruit IGF-1R to form a trimeric complex activating PI-3 K/Akt signaling and Src kinase and resulting in trastuzumab resistance. In erbB2+ breast cancer, interaction between erbB2 and erbB3 upregulates Survivin via a PI-3 K/Akt-dependent mechanism, and thereby confers paclitaxel resistance. In luminal B breast cancer, the erbB2/erbB3 hetero-dimers modulate ERα phosphorylation (activation) mainly through MEK/MAPK and/or PI-3 K/Akt signaling pathways, and subsequently alter tamoxifen sensitivity. These data support the hypothesis that targeting of erbB3 will significantly enhance the efficacy of those commonly used therapeutics in the treatment of erbB2+ breast cancer.

Article Snippet: It has been reported that erbB3 functions primarily to drive erbB2-mediated cell signaling [ , ].

Techniques: Activation Assay

Journal: Molecular Cancer

Article Title: Targeting of erbB3 receptor to overcome resistance in cancer treatment

doi: 10.1186/1476-4598-13-105

Figure Lengend Snippet: Current and novel therapeutic strategies targeting of erbB2 and/or erbB3 receptors for cancer therapy. Several erbB2-targeted therapies (trastuzumab, pertuzumab, T-DM1, and lapatinib) have being used in clinic, whereas no erbB3-targeted therapy has been approved for cancer treatment. Blocking Abs, such as MM-121, MM-111, AMG 888/U3-1287, and MP-RM-1/EV20, are the only agents being tested in early clinical and/or preclinical investigations. Our recent data show that entinostat, a class I HDAC inhibitor selectively downregulates erbB2/erbB3 via induction of specific miRNAs, miR-125a, miR-125b, and miR-205 in erbB2+ breast cancer cells. Further characterization demonstrates that these “sister” miRNAs (share common targets) act in concert to inhibit erbB2/erbB3 protein translation. Thus, the novel strategy, like cooperative miRNA targeting of erbB2/erbB3 may represent a new approach for cancer therapy.

Article Snippet: It has been reported that erbB3 functions primarily to drive erbB2-mediated cell signaling [ , ].

Techniques: Blocking Assay

Journal: Lung Cancer Management

Article Title: HER3 expression and MEK activation in non-small-cell lung carcinoma

doi: 10.2217/lmt-2020-0031

Figure Lengend Snippet: (A) Panel of HER3 negative cases (0–1+) and HER3 positive cases (2–3+). For HER3 staining, the guidelines from CAP HER2 scoring guidelines were used to generate an ad-hoc HER2 like score. (B) Kaplan–Meier curve of HER3 positive versus HER3 negative cases. (C) ERBB3 gene copy number and HER3 immunohistochemistry.

Article Snippet: Briefly, HER3 immunoreactivity was investigated using the rabbit monoclonal anti-HER3 antibody clone D22C5 (#12708, Cell Signaling Technology, London, UK).

Techniques: Staining, Immunohistochemistry

Journal: Lung Cancer Management

Article Title: HER3 expression and MEK activation in non-small-cell lung carcinoma

doi: 10.2217/lmt-2020-0031

Figure Lengend Snippet: Membranous HER3 and HER2 protein expression by immunohistochemistry.

Article Snippet: Briefly, HER3 immunoreactivity was investigated using the rabbit monoclonal anti-HER3 antibody clone D22C5 (#12708, Cell Signaling Technology, London, UK).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Lung Cancer Management

Article Title: HER3 expression and MEK activation in non-small-cell lung carcinoma

doi: 10.2217/lmt-2020-0031

Figure Lengend Snippet: Clinical characteristics for HER3 positive and HER3 negative patients.

Article Snippet: Briefly, HER3 immunoreactivity was investigated using the rabbit monoclonal anti-HER3 antibody clone D22C5 (#12708, Cell Signaling Technology, London, UK).

Techniques: